FDA Disease Models Will Focus On Areas With Poor R&D Track Records
Executive Summary
FDA's disease state modeling efforts may focus on therapeutic areas which traditionally have suboptimal drug development, Office of Clinical Pharmacology & Biopharmaceutics Director Larry Lesko said
You may also be interested in...
FDA Probes How To Compile Clinical Trial Data; Legal, Scientific Barriers Remain
Despite having gathered large amounts of clinical trial data through the years, FDA faces challenges when it comes to analyzing the data outside of the original scope in which it was collected
FDA Probes How To Compile Clinical Trial Data; Legal, Scientific Barriers Remain
Despite having gathered large amounts of clinical trial data through the years, FDA faces challenges when it comes to analyzing the data outside of the original scope in which it was collected
Industry Encouraged To Spread Its Wings In Learn Phase of Adaptive Trials
While FDA is granting industry a great deal of leeway in designing early, learn-phase adaptive trial models, the agency is suggesting that emphasis be placed on dose response and exposure risk, FDA officials indicated at a recent Pharmaceutical Research & Manufacturers of America workshop